. Disponible-sur, Prevalence and penetrance of brca1 and brca2 mutations in a population-based series of breast cancer cases Anglian Breast Cancer Study Group Disponible sur: http://www.e-cancer, 1301?8. 3. Prédispositions génétiques -facteurs de risque | Institut National Du Cancer, p.22, 2000.

C. Lord and A. Ashworth, The DNA damage response and cancer therapy, Nature, vol.146, issue.7381, pp.287-94, 2012.
DOI : 10.1016/j.cell.2011.07.042

R. Roy, J. Chun, and S. Powell, BRCA1 and BRCA2: Different roles in a common pathway of genome protection):68?78. 7. Breast cancer information core (breast cancer mutation database) Online Research Resources Developed at NHGRI. Disponible sur: https, Nat Rev Cancer, vol.23121, 2011.

A. Monteiro, BRCA1: the enigma of tissue-specific tumor development, Trends in Genetics, vol.19, issue.6, pp.312-317, 2003.
DOI : 10.1016/S0168-9525(03)00110-0

A. Knudson, Mutation and Cancer: Statistical Study of Retinoblastoma, Proceedings of the National Academy of Sciences, vol.68, issue.4, pp.820-823, 1971.
DOI : 10.1073/pnas.68.4.820

URL : http://www.pnas.org/content/68/4/820.full.pdf

S. Gayther, W. Warren, S. Mazoyer, P. Russell, P. Harrington et al., Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotypephenotype correlation Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, 1694?706. 12. Meric-Bernstam F, 1995.

A. Angulo, Genotype in BRCA-associated breast cancers The contribution of BRCA1 and BRCA2 to ovarian cancer, 87?91. 13. Ramus SJ, Gayther SA, pp.138-50, 2009.

S. Chen and G. Parmigiani, Meta-analysis of BRCA1 and BRCA2 penetrance, J Clin Oncol Off J Am Soc

N. Mavaddat, S. Peock, D. Frost, S. Ellis, R. Platte et al., 1329?33. 16 Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies, Clin Oncol J Natl Cancer Inst. 5 juin Am J Hum Genet. mai, vol.2510572, issue.11115, pp.1117-1147, 2003.

N. Mavaddat, D. Barrowdale, I. Andrulis, S. Domchek, D. Eccles et al., Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, janv, vol.21, issue.1, pp.134-181, 2012.

N. Andrieu, D. Goldgar, D. Easton, M. Rookus, R. Brohet et al., Response: Re: Pregnancies, Breastfeeding, and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study (IBCCS), JNCI Journal of the National Cancer Institute, vol.99, issue.6, pp.535-579, 2006.
DOI : 10.1093/jnci/djk091

URL : https://academic.oup.com/jnci/article-pdf/99/14/1131/7689409/djm041.pdf

Y. Tai, S. Domchek, G. Parmigiani, S. Chen, E. Kauffman et al., Breast Cancer Risk Among Male BRCA1 and BRCA2 Mutation Carriers, 1811?4. 21. Gleicher S, 2007.
DOI : 10.1093/jnci/94.11.844

URL : https://academic.oup.com/jnci/article-pdf/99/23/1811/7688930/djm203.pdf

P. Goodwin, K. Phillips, D. West, M. Ennis, J. Hopper et al., The Prostate. sept 2016 Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study, Metastatic Prostate Cancer in BRCA2 Mutation Carriers1135?45. 22, pp.19-26, 2012.

J. De-la-cruz, F. Andre, R. Harrell, R. Bassett, B. Arun et al., Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing, Human Pathology, vol.43, issue.11, pp.1932-1941, 2012.
DOI : 10.1016/j.humpath.2012.02.002

B. Arun, K. Vogel, A. Lopez, M. Hernandez, D. Atchley et al., High Prevalence of Preinvasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers, Cancer Prevention Research, vol.2, issue.2, pp.122-129, 2009.
DOI : 10.1158/1940-6207.CAPR-08-0050

URL : http://cancerpreventionresearch.aacrjournals.org/content/canprevres/2/2/122.full.pdf

P. Shah, M. Rosen, J. Stopfer, J. Siegfried, R. Kaltman et al., Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence, Breast Cancer Research and Treatment, vol.295, issue.20, pp.539-585, 2009.
DOI : 10.1093/jnci/djg050

S. Lakhani, M. Van-de-vijver, J. Jacquemier, T. Anderson, P. Osin et al., The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers, J Clin Oncol Off J Am Soc Clin Oncol. 1 mai Ann Surg Oncol. oct Breast Cancer Res Treat. janv, vol.2021137, issue.27101, pp.3324-3333, 2002.

M. Hall, J. Reid, R. Wenstrup, M. Schmidt, . Van-'t et al., Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis):e0120189. 31. Couch FJ, Nathanson KL, Offit K. Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention, 1579?85. 30. Van den Broek AJ, pp.2143-53, 2008.

N. Tung, C. Battelli, A. B. Kaldate, R. Bhatnagar, S. Bowles et al., Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 1 janv 2015 Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1, 25?33. 34, pp.95-102, 2017.

S. Masciari, D. Dillon, M. Rath, M. Robson, J. Weitzel et al., Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort, Breast Cancer Research and Treatment, vol.365, issue.14, pp.1125-1155, 2012.
DOI : 10.1056/NEJMoa0910383

URL : http://europepmc.org/articles/pmc3709568?pdf=render

J. Ngeow, K. Sesock, and C. Eng, Breast cancer risk and clinical implications for germline PTEN mutation carriers, Breast Cancer Research and Treatment, vol.202, issue.4, 2015.
DOI : 10.1159/000051684

J. Mester and C. E. , PTEN hamartoma tumor syndrome, Handb Clin Neurol, vol.132, pp.129-166, 2015.
DOI : 10.1016/B978-0-444-62702-5.00009-3

S. Hansford, P. Kaurah, H. Li-chang, M. Woo, J. Senz et al., Hereditary Diffuse Gastric Cancer Syndrome, JAMA Oncology, vol.1, issue.1, pp.23-32, 2015.
DOI : 10.1001/jamaoncol.2014.168

W. Lim, S. Olschwang, J. Keller, A. Westerman, F. Menko et al., Relative frequency and morphology of cancers in STK11 mutation carriers1 ???, Gastroenterology, vol.126, issue.7, pp.1788-94, 2004.
DOI : 10.1053/j.gastro.2004.03.014

N. Howlett, T. Taniguchi, S. Olson, B. Cox, Q. Waisfisz et al., Biallelic Inactivation of BRCA2 in Fanconi Anemia, Science, vol.297, issue.5581, pp.606-615, 2002.
DOI : 10.1126/science.1073834

C. Cybulski, W. Klu?niak, T. Huzarski, D. Woko?orczyk, A. Kashyap et al., Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families, Lancet Oncol. juin Breast Cancer Res BCR, vol.167, issue.61, pp.93-100, 2005.

J. Palacios, E. Honrado, A. Osorio, A. Cazorla, D. Sarrió et al., Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers

F. Aloraifi, M. Alshehhi, T. Mcdevitt, N. Cody, M. Meany et al., Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer):641?6. 47. INSERM. Risques héréditaires de cancers du sein et de l'ovaire : Quelle prise en charge ? 1998. 48 al. A new scoring system for the diagnosis of BRCA1/2 associated breast-ovarian cancer predisposition Disponible sur: https, Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. mai Bull Cancer, vol.4198, issue.57, 2011.

A. Antoniou, P. Pharoah, P. Smith, and D. Easton, The BOADICEA model of genetic susceptibility to breast and ovarian cancer, 1580?90. 50. INCA. RECOMMANDATIONS PROFESSIONNELLES: Femmes porteuses d'une mutation BRCA1 ou, 2004.
DOI : 10.1002/1097-0215(20001215)88:6<998::AID-IJC25>3.0.CO;2-0

K. Hill, E. Warner, I. Obdeijn, R. Kaas, M. Tilanus-linthorst et al., The attitudes of women with BRCA1 and BRCA2 mutations toward clinical breast examinations and breast self-examinations BRCA1- associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study, J Womens Health J Clin Oncol Off J Am Soc Clin Oncol, vol.1828, issue.736, pp.5265-73, 2002.

A. Maurice, D. Evans, J. Affen, R. Greenhalgh, S. Duffy et al., Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit, International Journal of Cancer, vol.37, issue.2, pp.417-442, 2012.
DOI : 10.1016/S0959-8049(01)00207-6

F. Sardanelli, F. Podo, F. Santoro, S. Manoukian, S. Bergonzi et al., Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk Italian 1 Study), Investigative Radiology, vol.46, issue.2, pp.94-105, 2011.
DOI : 10.1097/RLI.0b013e3181f3fcdf

E. Warner, P. Causer, J. Wong, F. Wright, R. Jong et al., Improvement in DCIS Detection Rates by MRI Over Time in a High-Risk Breast Screening Study, ):9?17. 56. Obdeijn I-M, 2011.
DOI : 10.1148/radiol.2533082026

X. Phi, S. Saadatmand, D. Bock, G. Warner, E. Sardanelli et al., Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study, Br J Cancer. 15 mars BMJ, vol.114345, issue.6, p.5660, 2012.

C. Colin, C. Devic, A. Noël, M. Rabilloud, M. Zabot et al., DNA double-strand breaks induced by mammographic screening procedures in human mammary epithelial cells Association of riskreducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer, ):1103?12. 60. Domchek SM,):967?75. 61. Kaas R,488?92. 62. Heemskerk-Gerritsen B a. M, Menke-Pluijmers MBE, 2010.

L. Obdeijn and I. , Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers, 222?31. 64. Rebbeck TR, pp.80-87, 2009.

D. Cibula, M. Zikan, L. Dusek, and O. Majek, Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis, 1197?207. 66. Moorman PG, 2011.

S. Iodice, M. Barile, N. Rotmensz, I. Feroce, B. Bonanni et al., Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis, European Journal of Cancer, vol.46, issue.12, pp.2275-84, 1990.
DOI : 10.1016/j.ejca.2010.04.018

J. Kotsopoulos, J. Lubinski, P. Moller, H. Lynch, C. Singer et al., Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers, Breast Cancer Research and Treatment, vol.56, issue.6, pp.579-86, 2014.
DOI : 10.1016/S0010-7824(97)00172-8

M. Kumle, E. Weiderpass, T. Braaten, I. Persson, H. Adami et al., Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol Progestagens use before menopause and breast cancer risk according to histology and hormone receptors, nov Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. oct, vol.1117, issue.1110, pp.2723-2731, 2002.

T. Soini, R. Hurskainen, S. Grénman, J. Mäenpää, J. Paavonen et al., Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study, Acta Oncologica, vol.91, issue.2, pp.188-92, 2016.
DOI : 10.1007/s10549-013-2500-7

T. Soini, R. Hurskainen, S. Grénman, J. Mäenpää, J. Paavonen et al., Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland Pt 1):292?9. 73. Obdeijn I Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition, Obstet Gynecol. août Breast Cancer Res Treat. janv, vol.124119, issue.22, pp.399-407, 2010.
DOI : 10.1097/aog.0000000000000356

URL : http://pdfs.journals.lww.com/greenjournal/2014/08000/Cancer_Risk_in_Women_Using_the.13.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1504231446035;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzddI9yZMOXhrzL4hhvIuyRpcXlkpCvDMUhE9m0cN9EOtWdKnB66gy5DnjaQWdI8s6/;hash|TfTubcb92fjPBejbe+/IcQ==

X. Phi, N. Houssami, I. Obdeijn, E. Warner, F. Sardanelli et al., Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ? 50 years: evidence from an individual patient data meta-analysis Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density, J Clin Oncol Off J Am Soc Clin Oncol. 1 févr J Clin Oncol Off J Am Soc Clin Oncol, vol.3333, issue.410, pp.1128-1163, 2015.

E. Warner, K. Hill, P. Causer, D. Plewes, R. Jong et al., A Prospective Study of Breast Cancer Incidence and Stage Distribution in Women with a BRCA1 or BRCA2 Mutation under Surveillance with and without Magnetic Resonance Imaging., Cancer Research, vol.69, issue.24 Supplement, pp.1664-1673, 2011.
DOI : 10.1158/0008-5472.SABCS-09-26

E. Warner, P. Causer, K. Hill, S. Messner, and J. Wong, Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 1 sept Long-term results of screening with magnetic resonance imaging in women with BRCA mutations, Br J Cancer. 26 juin, vol.117107, issue.171, pp.24-30, 2011.

E. Chéreau, C. Uzan, C. Balleyguier, C. J. De-paillerets, B. Caron et al., Characteristics, Treatment, and Outcome of Breast Cancers Diagnosed in BRCA1 and BRCA2 Gene Mutation Carriers in Intensive Screening Programs Including Magnetic Resonance Imaging, Clinical Breast Cancer, vol.10, issue.2, pp.113-121, 2010.
DOI : 10.3816/CBC.2010.n.022

D. Evans, E. Gareth, N. Kesavan, K. Nisha, Y. Lim et al., Erratum to: MRI breast screening in high-risk women: cancer detection and survival analysis, 663?72. 81. Saadatmand S, 2014.
DOI : 10.1007/s10549-014-3106-4

URL : https://link.springer.com/content/pdf/10.1007%2Fs10549-014-3106-4.pdf

J. Ramalho, R. Semelka, M. Ramalho, R. Nunes, M. Alobaidy et al., Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update, ):1192?8. 84. European Medicines Agency -Human medicines -Gadolinium-containing contrast agents, 2016.
DOI : 10.1111/j.1600-0560.2009.01283.x

URL : http://www.ajnr.org/content/ajnr/37/7/1192.full.pdf

. Disponible-sur, mammaire : technique, indications et résultats normaux, 2016.

V. Disponible-sur-king, Y. Gu, J. Kaplan, J. Brooks, M. Pike et al., Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging Breast magnetic resonance imaging findings in women treated with toremifene for premenstrual mastalgia, ):137?44. 88):984?9. 91. King V The effect of acute aromatase inhibition on breast parenchymal enhancement in magnetic resonance imaging: a prospective pilot clinical trial, pp.670-678, 1987.

N. N. Menopause, S. Raza, and R. Birdwell, Patterns of nonmasslike enhancement at screening breast MR imaging of high-risk premenopausal women, 420?5. 93. Giess CS, pp.1343-60, 2012.

J. Li, D. Dershaw, C. Lee, C. Lee, S. Joo et al., Breast MRI after conservation therapy: usual findings in routine follow-up examinations Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy The impact of bilateral salpingo-oophorectomy on breast MRI background parenchymal enhancement and fibroglandular tissue, ):799?807. 95. DeLeo MJ,669?73. 96. Price ER, Brooks JD, pp.162-170, 2010.

Y. Kim, S. Kim, B. Choi, B. Kang, H. Kim et al., Impact of Radiotherapy on Background Parenchymal Enhancement in Breast Magnetic Resonance Imaging, Asian Pacific Journal of Cancer Prevention, vol.15, issue.7, pp.2939-2982, 2014.
DOI : 10.7314/APJCP.2014.15.7.2939

URL : http://ocean.kisti.re.kr/downfile/volume/apocp/POCPA9/2014/v15n7/POCPA9_2014_v15n7_2939.pdf

J. Sogani, E. Morris, J. Kaplan, D. 'alessio, D. Goldman et al., Comparison of Background Parenchymal Enhancement at Contrast-enhanced Spectral Mammography and Breast MR Imaging, Radiology, vol.282, issue.1, pp.63-73, 2017.
DOI : 10.1148/radiol.2016160284

URL : http://europepmc.org/articles/pmc5207122?pdf=render

L. Zeng, G. Lo, H. Moshonov, J. Liang, D. Hodgson et al., Breast Background Parenchymal Enhancement on Screening Magnetic Resonance Imaging in Women Who Received Chest Radiotherapy for Childhood Hodgkin's Lymphoma, Academic Radiology, vol.23, issue.2, pp.168-75, 2016.
DOI : 10.1016/j.acra.2015.09.010

C. Giess, E. Yeh, S. Raza, and R. Birdwell, Background Parenchymal Enhancement at Breast MR Imaging: Normal Patterns, Diagnostic Challenges, and Potential for False-Positive and False-Negative Interpretation, RadioGraphics, vol.34, issue.1, pp.234-281, 2014.
DOI : 10.1148/rg.341135034

A. Talele, P. Slanetz, W. Edmister, E. Yeh, and D. Kopans, The Lactating Breast: MRI Findings and Literature Review, The Breast Journal, vol.203, issue.3, pp.237-277, 2003.
DOI : 10.1148/radiology.203.1.9122382

L. Espinosa, B. Daniel, L. Vidarsson, M. Zakhour, D. Ikeda et al., The Lactating Breast: Contrast-enhanced MR Imaging of Normal Tissue and Cancer, Radiology, vol.237, issue.2, pp.429-465, 2005.
DOI : 10.1148/radiol.2372040837

D. Taylor, J. Lazberger, A. Ives, E. Wylie, and C. Saunders, Reducing delay in the diagnosis of pregnancy-associated breast cancer: How imaging can help us, Journal of Medical Imaging and Radiation Oncology, vol.161, issue.1, pp.33-42, 2011.
DOI : 10.2214/ajr.161.5.8273635

J. Chen, H. Yu, M. Lin, R. Mehta, and M. Su, Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI, Magnetic Resonance Imaging, vol.31, issue.9
DOI : 10.1016/j.mri.2013.07.014

V. King, J. Brooks, J. Bernstein, A. Reiner, M. Pike et al., Background Parenchymal Enhancement at Breast MR Imaging and Breast Cancer Risk, Radiology, vol.260, issue.1, pp.50-60, 2011.
DOI : 10.1148/radiol.11102156

S. Jansen, V. Lin, M. Giger, H. Li, G. Karczmar et al., Normal parenchymal enhancement patterns in women undergoing MR screening of the breast, European Radiology, vol.116, issue.2, pp.1374-82, 2011.
DOI : 10.1016/S0022-3476(05)82925-7

N. Hambly, L. Liberman, D. Dershaw, S. Brennan, and E. Morris, Background Parenchymal Enhancement on Baseline Screening Breast MRI: Impact on Biopsy Rate and Short-Interval Follow-Up, American Journal of Roentgenology, vol.196, issue.1
DOI : 10.2214/AJR.10.4550

URL : http://www.ajronline.org/content/196/1/218.full.pdf+html

B. Bennani-baiti, M. Dietzel, and P. Baltzer, MRI Background Parenchymal Enhancement Is Not Associated with Breast Cancer, PLOS ONE, vol.183, issue.7, p.158573, 2016.
DOI : 10.1371/journal.pone.0158573.s001

URL : https://doi.org/10.1371/journal.pone.0158573

C. Vachon, C. Van-gils, T. Sellers, K. Ghosh, S. Pruthi et al., Mammographic density, breast cancer risk and risk prediction, Breast Cancer Research, vol.39, issue.6, p.217, 2007.
DOI : 10.1088/0031-9155/39/10/008

URL : https://breast-cancer-research.biomedcentral.com/track/pdf/10.1186/bcr1829?site=breast-cancer-research.biomedcentral.com

N. Boyd, H. Guo, L. Martin, L. Sun, J. Stone et al., Mammographic Density and the Risk and Detection of Breast Cancer, New England Journal of Medicine, vol.356, issue.3, pp.227-263, 2007.
DOI : 10.1056/NEJMoa062790

G. Ursin, H. Ma, A. Wu, L. Bernstein, M. Salane et al., Mammographic density and breast cancer in three ethnic groups, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. avr, vol.12, issue.4, pp.332-340, 2003.

B. Dontchos, H. Rahbar, S. Partridge, L. Korde, D. Lam et al., Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?, Radiology, vol.276, issue.2, pp.371-80, 2015.
DOI : 10.1148/radiol.2015142304

T. Rebbeck, T. Friebel, T. Wagner, H. Lynch, J. Garber et al., Mutation Carriers: The PROSE Study Group, Journal of Clinical Oncology, vol.23, issue.31, pp.7804-7814, 2005.
DOI : 10.1200/JCO.2004.00.8151

A. Scaranelo, M. Carrillo, R. Fleming, L. Jacks, S. Kulkarni et al., Pilot Study of Quantitative Analysis of Background Enhancement on Breast MR Images: Association with Menstrual Cycle and Mammographic Breast Density, Radiology, vol.267, issue.3, pp.692-700, 2013.
DOI : 10.1148/radiol.13120121

P. Vogel, N. Georgiade, B. Fetter, F. Vogel, and K. Mccarty, The correlation of histologic changes in the human breast with the menstrual cycle, Am J Pathol. juill, vol.104, issue.1, pp.23-34, 1981.

C. Potten, R. Watson, G. Williams, S. Tickle, S. Roberts et al., The effect of age and menstrual cycle upon proliferative activity of the normal human breast, British Journal of Cancer, vol.58, issue.2, pp.163-70, 1988.
DOI : 10.1038/bjc.1988.185

P. Fowler, C. Casey, G. Cameron, M. Foster, and C. Knight, Cyclic changes in composition and volume of the breast during the menstrual cycle, measured by magnetic resonance imaging, BJOG: An International Journal of Obstetrics and Gynaecology, vol.104, issue.7, pp.595-602, 1990.
DOI : 10.1038/bjc.1988.185

P. Gerhardt, Recommandations du Comité pour les exigences de qualité de l'imagerie par résonance magnétique de l'IRM du sein, Jahresber Dtsch Rontgengesell, 1995.

J. Delille, P. Slanetz, E. Yeh, D. Kopans, and L. Garrido, Physiologic Changes in Breast Magnetic Resonance Imaging during the Menstrual Cycle: Perfusion Imaging, Signal Enhancement, and Influence of the T1 Relaxation Time of Breast Tissue, The Breast Journal, vol.109, issue.4, pp.236-277, 2005.
DOI : 10.1016/0002-9378(71)90872-6

A. Teifke, A. Hlawatsch, T. Beier, W. Vomweg, T. Schadmand et al., Undetected Malignancies of the Breast: Dynamic Contrast-enhanced MR Imaging at 1.0 T, Radiology, vol.224, issue.3, pp.881-889, 2002.
DOI : 10.1148/radiol.2243010547

A. Shimauchi, S. Jansen, H. Abe, N. Jaskowiak, R. Schmidt et al., Breast Cancers Not Detected at MRI: Review of False-Negative Lesions, American Journal of Roentgenology, vol.194, issue.6, pp.1674-1683, 2010.
DOI : 10.2214/AJR.09.3568

T. Uematsu, M. Kasami, and J. Watanabe, Does the degree of background enhancement in breast MRI affect the detection and staging of breast cancer?, European Radiology, vol.203, issue.11, pp.2261-2268, 2011.
DOI : 10.1148/radiology.203.1.9122383

M. Telegrafo, L. Rella, S. Ianora, A. Angelelli, G. Moschetta et al., Effect of background parenchymal enhancement on breast cancer detection with magnetic resonance imaging, Diagnostic and Interventional Imaging, vol.97, issue.3, pp.315-335, 2016.
DOI : 10.1016/j.diii.2015.12.006

URL : https://doi.org/10.1016/j.diii.2015.12.006

G. Abramovici and M. Mainiero, Screening Breast MR Imaging: Comparison of Interpretation of Baseline and Annual Follow-up Studies, Radiology, vol.259, issue.1, pp.85-91, 2011.
DOI : 10.1148/radiol.10101009

S. Brennan, J. Sung, D. Dershaw, L. Liberman, and E. Morris, Cancellation of MR Imaging???guided Breast Biopsy Due to Lesion Nonvisualization: Frequency and Follow-Up, Radiology, vol.261, issue.1, pp.92-101, 2011.
DOI : 10.1148/radiol.11100720

W. Demartini, F. Liu, S. Peacock, P. Eby, R. Gutierrez et al., Background Parenchymal Enhancement on Breast MRI: Impact on Diagnostic Performance, American Journal of Roentgenology, vol.198, issue.4, pp.373-380, 2012.
DOI : 10.2214/AJR.10.6272

B. Bignotti, A. Signori, F. Valdora, F. Rossi, M. Calabrese et al., Evaluation of background parenchymal enhancement on breast MRI: a systematic review, The British Journal of Radiology, vol.77, issue.1070, 2016.
DOI : 10.1059/0003-4819-155-8-201110180-00009

URL : http://europepmc.org/articles/pmc5685112?pdf=render

K. Hegenscheid, C. Schmidt, R. Seipel, R. Laqua, R. Ohlinger et al., Normal Breast Parenchyma: Contrast Enhancement Kinetics at Dynamic MR Mammography???Influence of Anthropometric Measures and Menopausal Status, Radiology, vol.266, issue.1, pp.72-80, 2013.
DOI : 10.1148/radiol.12112590